Whitepaper: Integrative and Comprehensive Approach to Inflammatory Bowel Disease
by Dr. Ronald L. Hoffman, MD, CNS, FACAM
Less than 1 percent of the U.S. population suffers from an inflammatory bowel disease (IBD), and yet TV commercials for IBD drugs still plaster the airwaves. These drugs are worth the advertisements cost because they’re expensive—sometimes tens of thousands of dollars per person per year—and the people with these conditions desperately need treatment.
Yet, IBD is often misunderstood. Several risk factors have been identified for the group of conditions that fall under the IBD label,
Thanks to the insistence of patients and their doctors, there have been new inroads into dietary treatments of IBD. Dr. Ronald Hoffman, MD, explains the current understanding of IBD, as well as the supplement and dietary approaches
SHARE